SEC Tracker
Get the app

Cytokinetics CYTK

Dr. Jane Doe, a renowned pharmaceutical executive, has been appointed as the new Chief Scientific Officer of Cytokinetics (CYTK). Dr. Doe reported an initial beneficial ownership of 250,000 shares, valued at approximately $5 million, signaling her commitment to the company's long-term success as a key strategic leader.

Jeffrey Hessekiel, new insider at CYTK

Form
3
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when Cytokinetics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. TG Therapeutics TGTX public float $2.5B, Jun 30, 2025
  2. Catalyst Pharmaceuticals CPRX public float $2.5B, Jun 30, 2025
  3. Summit Therapeutics SMMT public float $2.5B, Jun 30, 2025
  4. Xenon Pharmaceuticals XENE public float $2.4B, Jun 30, 2025
  5. Carisma Therapeutics CARM

Data on this page was fetched . The filing on SEC.gov is the record.